Cognito Therapeutics, a company specializing in non-invasive neuroprotective therapies for neurodegenerative diseases, announced the final close of its oversubscribed $105 million Series C funding.
The financing strengthens Cognito’s financial position as it advances toward pivotal data readout, regulatory submission, and commercial launch, while supporting continued clinical development of Spectris and expansion of launch readiness efforts ahead of anticipated market entry in 2027.
The Series C will also support advancement of the Spectris platform into additional neurodegenerative indications through their network of brain health collaboratories beginning with WVU Rockefeller Neuroscience Institute.
Spectris is an investigational physician-prescribed, at-home therapeutic platform designed to evoke coordinated neural activity, across interconnected networks, through non-invasive visual and auditory stimulation. By engaging neural network function through the brain’s natural sensory pathways, Spectris is being studied for its potential to preserve cognition, daily function, and brain structure in patients diagnosed with Alzheimer’s disease.
Spectris is an investigational device and is not approved by the U.S. Food and Drug Administration.
